HYUNDAI PHARMACEUTICAL CO., LTD.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1965-01-01
- Employees
- 501
- Market Cap
- -
HDDO-1756 Bio Equivalence Study
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Hyundai Pharmaceutical Co., LTD.
- Target Recruit Count
- 56
- Registration Number
- NCT04755894
- Locations
- 🇰🇷
Hyundai Pharm, Seoul, Korea, Republic of
BPDO-1603 Intervention Trial in Patients With Moderate-to-severe Alzheimer's Disease
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- Hyundai Pharmaceutical Co., LTD.
- Target Recruit Count
- 712
- Registration Number
- NCT04229927
- Locations
- 🇰🇷
Inha University Hospital, Incheon, Korea, Republic of
HDDO-1801 Intervention Trial
Phase 1
- Conditions
- Respiratory Disease
- Interventions
- Drug: Combinations
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Hyundai Pharmaceutical Co., LTD.
- Target Recruit Count
- 36
- Registration Number
- NCT04097951
- Locations
- 🇰🇷
Inha University Hospital, Junggu, Incheon, Korea, Republic of
HDDO-1614 Bio Equivalence Study
Phase 1
Completed
- Conditions
- Osteoporosis
- Interventions
- Combination Product: HDDO-1614
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- Hyundai Pharmaceutical Co., LTD.
- Target Recruit Count
- 38
- Registration Number
- NCT03382314
- Locations
- 🇰🇷
Inha University Hospital, Junggu, Incheon, Korea, Republic of
HDDO-1614 Intervention Trial
Phase 1
Completed
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2017-07-31
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Hyundai Pharmaceutical Co., LTD.
- Target Recruit Count
- 37
- Registration Number
- NCT03234244
- Locations
- 🇰🇷
Inha University Hospital, Junggu, Incheon, Korea, Republic of
Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Hyundai Pharmaceutical Co., LTD.
- Target Recruit Count
- 244
- Registration Number
- NCT02792946
To Evaluate Safety and the Pharmacokinetic Characteristics After Oral Administration of HT-003 Compared With Choline Alfoscerate Capsule in Healthy Adult Male Volunteers
- First Posted Date
- 2015-03-24
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Hyundai Pharmaceutical Co., LTD.
- Target Recruit Count
- 24
- Registration Number
- NCT02395926
Compare Safety and Pharmacokinetic Properties of Surfolase Capsule(Acebrophylline 100mg) and Surfolase CR(200mg)
Phase 1
Completed
- Conditions
- Healthy Male
- Interventions
- First Posted Date
- 2015-03-24
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Hyundai Pharmaceutical Co., LTD.
- Target Recruit Count
- 72
- Registration Number
- NCT02395913
Change From Baseline to Chronic Kidney Disease Patient Before and After Administration Drug
Phase 2
Completed
- Conditions
- Chronic Renal Failure
- Interventions
- Drug: PlaceboDrug: HD-003 (800mg/day)Drug: HD-003 (1600mg/day)
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Hyundai Pharmaceutical Co., LTD.
- Target Recruit Count
- 62
- Registration Number
- NCT02378194
Study to Evaluate the Effect of Food on the Pharmacokinetics of Surfolase CR Tablet in Healthy Volunteers
- First Posted Date
- 2015-02-27
- Last Posted Date
- 2015-02-27
- Lead Sponsor
- Hyundai Pharmaceutical Co., LTD.
- Target Recruit Count
- 25
- Registration Number
- NCT02373891
© Copyright 2025. All Rights Reserved by MedPath